#United States #New York #Class Action #Savara Inc. #SVRA

Savara Inc. Class Action Lawsuit Notification

In a significant development for investors, Levi & Korsinsky, LLP has announced a class action lawsuit against Savara Inc. (NASDAQ: SVRA), focused on alleged securities fraud that may have impacted shareholders during a crucial period. This notice serves as an essential call to those who may have been affected, as they have until November 7, 2025, to act.

Understanding the Allegations

The lawsuit centers around claims that from March 4, 2024, to May 23, 2025, the defendants made misleading statements regarding a treatment known as MOLBREEVI BLA, intended for pulmonary alveolar proteinosis (PAP). It is alleged that Savara Inc. concealed critical details about the treatment's chemistry and regulatory approval processes, particularly from the FDA.

These claims include that:

• - Sufficient information regarding MOLBREEVI’s chemistry was not available, leading to significant concerns about its approval from the FDA.
• - The timeline initially provided to investors regarding the submission of the MOLBREEVI application appeared overly optimistic in light of these challenges.
• - As a result, there was a heightened possibility that Savara would need to raise additional capital due to delays in regulatory approval, affecting the company's financial health and share value.

Impact on Investors

For shareholders of Savara Inc., this class action presents an opportunity to seek recovery for losses incurred during this timeframe. The suit points out that the public statements made by the company's leaders were materially false and misleading, which undeniably affected the financial decisions of investors. If you believe you were impacted by these events, it is crucial to stay informed about your rights and the potential for compensation.

How to Get Involved

Affected investors are encouraged to contact Levi & Korsinsky to explore their options. Assistance is available simply by reaching out via email or phone, where representatives can provide the necessary guidance. Importantly, there is no financial obligation to participate in this lawsuit; class members can claim compensation without incurring any fees.

Levi & Korsinsky’s Track Record

Levi & Korsinsky is not new to handling such high-stakes securities litigation. Over the past two decades, the firm has built a reputation for securing substantial recoveries for aggrieved shareholders, consistently ranked among the top securities litigation firms in the United States. With a dedicated team of over 70 professionals, they possess the expertise required to navigate complex legal landscapes, providing invaluable support to investors.

Next Steps for Affected Investors

As the deadline of November 7, 2025, approaches, it is essential for those who believe they have suffered losses due to this alleged fraud to take immediate action. Appointing oneself as a lead plaintiff is not a requirement to participate in the lawsuit, making this an accessible option for many shareholders.

For further inquiries, interested parties may contact:

• - Joseph E. Levi, Esq.

Email: [email protected]
Phone: (212) 363-7500

• - Or visit their website for more details and a submission form: Levi & Korsinsky.

In summary, Savara Inc. investors should stay alert to the winding paths ahead, as this class action lawsuit unfolds, offering a chance for recovery in light of challenging circumstances that have surfaced.